Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of DA-3880 vs Aranesp in Healthy Volunteers
NCT02241200Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Biosimilar
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DA-3880 in anemia (2 arms), sponsored by Dong-A ST. Primary endpoints: Pharmacokinetics of DA-3880 and Aranesp via IV Administration at 6 weeks and Pharmacokinetics of DA-3880 and Aranesp via SC Administration at 6 weeks. Started Aug 2014; status: completed.
02
Drugs
DA-3880
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02241200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241200.